Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts.
The phosphodiesterase (PDE) inhibitor isomazole increased the force of contraction to 278.3 +/- 89.1% (n = 7) of the predrug value in ventricular trabeculae carneae isolated from nonfailing human hearts. This effect can be attributed mainly to a PDE III or a combined PDE III/IV inhibition since at the concentration of the maximal positive inotropic effect of isomazole, PDE III and PDE IV were completely inhibited. In explanted failing human hearts (end-stage myocardial failure, NYHA IV), isomazole increased the force of contraction only marginally to 110.1 +/- 10.7% of the predrug value. The lack of a distinct positive inotropic efficacy of isomazole in failing human hearts could not be explained by an impairment of PDE inhibition since the properties of the PDE I-IV isoenzymes separated by DEAE-Sepharose chromatography and the inhibitory effects of isomazole did not differ in both preparations. The positive inotropic effect of the beta-adrenoceptor agonist isoprenaline was also reduced in failing hearts. However, in the presence of isomazole, the diminished positive inotropic effect of isoprenaline was restored to values obtained with isoprenaline alone in nonfailing hearts. Thus, the decreased effect of inotropic drugs like isoprenaline or isomazole in preparations from failing human heart might be explained mainly by a diminished cAMP formation due to a defect in receptor-adenylate cyclase coupling.
Bethke
T
T
Abteilung Allgemeine Pharmakologie, Universitäts-Krankenhaus Eppendorf Universität Hamburg, F.R.G.
Klimkiewicz
A
A
Kohl
C
C
von der Leyen
H
H
Mehl
H
H
Mende
U
U
Meyer
W
W
Neumann
J
J
Schmitz
W
W
Scholz
H
H
D000328:Adult; D002118:Calcium / Q000494:pharmacology; D002848:Chromatography, DEAE-Cellulose; D004558:Electric Stimulation; D005260:Female; D006321:Heart / Q000187:drug effects; D006333:Heart Failure / Q000201:enzymology / Q000503:physiopathology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D066298:In Vitro Techniques; D007527:Isoenzymes / Q000378:metabolism; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D020105:Milrinone; D009200:Myocardial Contraction / Q000187:drug effects*; D009206:Myocardium / Q000201:enzymology*; D010042:Ouabain / Q000031:analogs & derivatives / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D011724:Pyridazines / Q000494:pharmacology; D011728:Pyridones / Q000494:pharmacology
D007093:Imidazoles; D007527:Isoenzymes; D010726:Phosphodiesterase Inhibitors; D011724:Pyridazines; D011728:Pyridones; C000977:dihydroouabain; D010042:Ouabain; C047936:UD CG 212 Cl; D010727:Phosphoric Diester Hydrolases; C029758:sulmazole; D020105:Milrinone; D007545:Isoproterenol; D002118:Calcium